Through this partnership, BlueSphere will treat patients with acute myeloid and lymphocytic leukemia, and myeloid dysplastic syndrome, who have active disease or are at high risk for relapse, with the...
PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company utilizing a powerful TCR discovery platform to identify novel therapeutic candidates for...
TCX-101 Clinical Program: TCR T-Cell therapy product candidate (BSB-1001) to be delivered simultaneously with allogeneic stem cell transplant in patients with active disease or high risk of relapse ...
PITTSBURGH, May 30, 2024 (GLOBE NEWSWIRE) -- BlueSphere Bio, a drug development company focused on the discovery of novel T-cell receptor (TCR)-based therapies with a robust clinical pipeline and...
BlueSphere Bio to Present at the Next Generation CAR & T Cell Therapies Conference
BlueSphere Bio to Present at the 25th Annual BIO CEO & Investor Conference
BlueSphere Bio Appoints Erkut Bahceci, M.D., as Chief Medical Officer
PITTSBURGH, Nov. 10, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced the presentation of data supporting the potential of its first and lead product candidate, BSB-1001, at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held virtually and in Boston, MA from November 8-12, 2022.
PITTSBURGH, Nov. 03, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced that Robert Keefe, Ph.D., Chief Development Officer of BlueSphere Bio, will present data in a poster at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held virtually and in Boston, MA from November 8-12, 2022. Details for the poster presentation are shown below:
PITTSBURGH, Oct. 04, 2022 (GLOBE NEWSWIRE) -- BlueSphere Bio, a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, announced the appointment of Keir Loiacono, Esq. to Chief Executive Officer. Mr. Loiacono has played a key role as Chief Business Officer at BlueSphere over the last year, working closely with co-founders Drs. Mark and Warren Shlomchik, Dr. Bob Keefe, Chief Development Officer, and the broader team at BlueSphere. Mr. Loiacono will lead BlueSphere into the next phase of growth, as the company continues to build out its clinical and research activities.